<p>LIVZON PHARMA (01513.HK) announced its performance for the fiscal year 2025, achieving operating revenue of 12.02 billion RMB (same below), an increase of 1.8% year-on-year. The net profit attributable to shareholders was 2.023 billion RMB, a decline of 1.8%, with earnings per share of 2.24 RMB. A dividend of 14.3 RMB will be distributed for every 10 shares</p>

512010

588130

562050

01513

512170

512290

159506

510660

<p>LIVZON PHARMA announced its 2025 annual performance, achieving operating revenue of 12.02 billion RMB (same below), an increase of 1.8% year-on-year. The net profit attributable to shareholders was 2.023 billion RMB, a decline of 1.8%, with earnings per share of 2.24 RMB. A dividend of 14.3 RMB per 10 shares was declared</p>

AASTOCKS

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP CSI Pharmaceuticals ETF

LIVZON PHARMA

Hwabao WP CSI Medical Service ETF

Guotai CSI Bio-medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

"Performance" LIVZON PHARMA's annual net profit is RMB 2.023 billion, down 1.8%, with a dividend of RMB 14.3 per 10 shares